Abstract | OBJECTIVES: METHODS: Thirty-nine eligible patients with ovarian carcinoma persistent, progressive, or recurrent after initial treatment with paclitaxel 200 mg/m(2) over 24 h every 3 weeks received cisplatin 100 mg/m(2) every 3 weeks until disease progression or unacceptable toxicity. RESULTS: Among 37 patients evaluable for response, 8 complete (22%) and 13 partial (35%) responses resulted. Twelve (32%) patients exhibited stable disease, while 4 (11%) had increasing disease. Median progression-free survival was 11.0 months. Median survival was 15.0 months. All but two patients were clinically resistant to paclitaxel (progression during or within 6 months after completion of paclitaxel). Grade 2 or worse adverse effects among 39 patients evaluable for toxicity included neutropenia (23), thrombocytopenia (3), anemia (10), nausea and vomiting (23), azotemia (7), neurotoxicity (9), fever (2), and tinnitus (1). CONCLUSION: These data provide evidence that cisplatin is active as second-line therapy in patients clinically resistant to paclitaxel. The overall response rate is high (57%) with excellent progression-free and overall survival in the second-line setting.
|
Authors | J Tate Thigpen, John A Blessing, George Olt, Samuel S Lentz, Jeffrey Bell |
Journal | Gynecologic oncology
(Gynecol Oncol)
Vol. 90
Issue 3
Pg. 581-6
(Sep 2003)
ISSN: 0090-8258 [Print] United States |
PMID | 13678728
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Antineoplastic Agents
- Paclitaxel
- Cisplatin
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents
(adverse effects, therapeutic use)
- Cisplatin
(adverse effects, therapeutic use)
- Disease Progression
- Disease-Free Survival
- Drug Administration Schedule
- Drug Resistance, Neoplasm
- Female
- Humans
- Middle Aged
- Neoplasm Recurrence, Local
(drug therapy)
- Ovarian Neoplasms
(drug therapy)
- Paclitaxel
(therapeutic use)
|